SRR1472079
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.399
- COAGULATION+0.309
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.301
- MYOGENESIS+0.235
- PANCREAS_BETA_CELLS+0.219
- SPERMATOGENESIS+0.201
- HEDGEHOG_SIGNALING+0.198
- APICAL_SURFACE+0.168
- BILE_ACID_METABOLISM+0.165
- ESTROGEN_RESPONSE_LATE+0.132
Top 10 suppressed
- MYC_TARGETS_V1-0.665
- MYC_TARGETS_V2-0.570
- UNFOLDED_PROTEIN_RESPONSE-0.536
- DNA_REPAIR-0.531
- MTORC1_SIGNALING-0.516
- PROTEIN_SECRETION-0.508
- OXIDATIVE_PHOSPHORYLATION-0.482
- E2F_TARGETS-0.458
- CHOLESTEROL_HOMEOSTASIS-0.455
- G2M_CHECKPOINT-0.407
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1375635 | GTEX | — | 0.976 |
| 2 | SRR1394713 | GTEX | — | 0.972 |
| 3 | SRR1339549 | GTEX | — | 0.971 |
| 4 | SRR1486863 | GTEX | — | 0.968 |
| 5 | SRR1479759 | GTEX | — | 0.962 |
| 6 | SRR1434138 | GTEX | — | 0.962 |
| 7 | SRR1330061 | GTEX | — | 0.960 |
| 8 | SRR1339530 | GTEX | — | 0.960 |
| 9 | SRR1409534 | GTEX | — | 0.958 |
| 10 | SRR1451964 | GTEX | — | 0.957 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.399 | Remibrutinib | — uncovered |
| COAGULATION | 0.309 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.301 | Inavolisib | — uncovered |
| MYOGENESIS | 0.235 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.219 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.201 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.198 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.168 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.165 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.132 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.122 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.095 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.094 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.087 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.081 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.071 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.063 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.004 | Inavolisib | — uncovered |